NCT00235287|UnknownPhase 4DMC
Loading search results
Sponsor study identifier
interventional
60
1 country
1
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThe purpose of this study is to determine whether a combination therapy with angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers reduces the arterial stiffness assessed by applantiontonometry more than a single treatment in kidney patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
October 6, 2005
Actual (reported)October 10, 2005
Actual (reported)pulse wave velocity (aortic and brachial)
0, 8, 16 and 24 weeks after start of intervention
augmentation index
0, 8, 16 and 24 weeks after start of intervention
blood pressure (brachial and aortic)
0, 8, 16 and 24 weeks after start of intervention
buckbergs index
0, 8, 16 and 24 weeks after start of interven
time to reflection
0, 8, 16 and 24 weeks after start of interven
pulse pressure
0, 8, 16 and 24 weeks after start of interven
24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Candesartan and enalapril
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordGrouped treatment entry
candesartan and enalapril
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordGrouped treatment entry
candesartan and enalapril
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordGrouped treatment entry
candesartan and enalapril
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordDept. of Nephrology, Herlev University Hospital
Herlev, 2730, Denmark
Cooper TE, Teng C, Tunnicliffe DJ, Cashmore BA, Strippoli GF. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD007751. doi: 10.1002/14651858.CD007751.pub3.
Frimodt-Moller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial. PLoS One. 2012;7(7):e41757. doi: 10.1371/journal.pone.0041757. Epub 2012 Jul 31.
Marie Frimodt-Møller, MD
Dept. of Nephrology, Herlev University Hospital
First Submitted
October 6, 2005
First Posted
October 10, 2005
Study Start
September 2005
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
January 19, 2009
Record last verified: 2009-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis
8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Linked from the registry description. Each source intervention is retained as reported.
In: Candesartan and enalapril
In: Candesartan and enalapril
In: candesartan and enalapril
In: candesartan and enalapril
In: candesartan and enalapril
In: candesartan and enalapril
In: candesartan and enalapril
In: candesartan and enalapril
Contact the study team to confirm eligibility.